東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Development of a DNA vaccine against...

Kapczynski, Darrell Roman.

Linked to FindBook

Google Book

Amazon

博客來

Development of a DNA vaccine against infectious bronchitis using the S1 gene from Arkansas serotype of infectious bronchitis virus: Protective immunity against infectious bronchitis virus following intramuscular or in ovo DNA vaccination.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Development of a DNA vaccine against infectious bronchitis using the S1 gene from Arkansas serotype of infectious bronchitis virus: Protective immunity against infectious bronchitis virus following intramuscular or in ovo DNA vaccination./
Author:	Kapczynski, Darrell Roman.
Description:	176 p.
Notes:	Source: Dissertation Abstracts International, Volume: 60-11, Section: B, page: 5338.
Contained By:	Dissertation Abstracts International60-11B.
Subject:	Biology, Microbiology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=9949454
ISBN:	059951860X

Development of a DNA vaccine against infectious bronchitis using the S1 gene from Arkansas serotype of infectious bronchitis virus: Protective immunity against infectious bronchitis virus following intramuscular or in ovo DNA vaccination.
Kapczynski, Darrell Roman.

Development of a DNA vaccine against infectious bronchitis using the S1 gene from Arkansas serotype of infectious bronchitis virus: Protective immunity against infectious bronchitis virus following intramuscular or in ovo DNA vaccination. - 176 p.

Source: Dissertation Abstracts International, Volume: 60-11, Section: B, page: 5338.

Thesis (Ph.D.)--University of Georgia, 1998.

A DNA vaccine against infectious bronchitis virus was developed using the S1 gene from the Arkansas serotype of IBV. The polymerase chain reaction (PCR) was used to amplify the S1, glycoprotein gene from viral genomic RNA and ligated into the pcDNA 3.1(+) vector (Invitrogen, San Diego, CA) under control of the CMV immediate early promoter to create plasmid pDKArkS1-DPI.

ISBN: 059951860XSubjects--Topical Terms:

1017734
Biology, Microbiology.

Development of a DNA vaccine against infectious bronchitis using the S1 gene from Arkansas serotype of infectious bronchitis virus: Protective immunity against infectious bronchitis virus following intramuscular or in ovo DNA vaccination.
LDR:03496nmm 2200313 4500 001 1855714
005 20040629073629.5
008 130614s1998 eng d
020 $a 059951860X
035 $a (UnM)AAI9949454
035 $a AAI9949454
040 $a UnM $c UnM
100 1 $a Kapczynski, Darrell Roman. $3 1943517
245 1 0 $a Development of a DNA vaccine against infectious bronchitis using the S1 gene from Arkansas serotype of infectious bronchitis virus: Protective immunity against infectious bronchitis virus following intramuscular or in ovo DNA vaccination.
300 $a 176 p.
500 $a Source: Dissertation Abstracts International, Volume: 60-11, Section: B, page: 5338.
500 $a Director: Mark W. Jackwood.
502 $a Thesis (Ph.D.)--University of Georgia, 1998.
520 $a A DNA vaccine against infectious bronchitis virus was developed using the S1 gene from the Arkansas serotype of IBV. The polymerase chain reaction (PCR) was used to amplify the S1, glycoprotein gene from viral genomic RNA and ligated into the pcDNA 3.1(+) vector (Invitrogen, San Diego, CA) under control of the CMV immediate early promoter to create plasmid pDKArkS1-DPI.
520 $a Vaccination of chickens with pDKArkS1-DPI was examined using a dose titration method. Antibody and virus-neutralization titers increased in all virus challenged groups during the course of the experiment. IBV was detected up to 10 days post-challenge in tracheal samples taken from unvaccinated control groups. Birds receiving commercial live or DNA vaccine cleared challenge virus from trachea samples after 5 days post-challenge as determined by RT-PCR. Birds vaccinated with the highest amount of DNA were 100% protected from clinical disease. Birds receiving a live commercial IBV vaccine were 90% protected from clinical disease. Negative control group birds were ≤40% protected from the disease.
520 $a Immunological responses following vaccination with pDKArkS1-DPI was examined by <italic>in ovo</italic> vaccination of chicken embryos at 18 days of age. After hatch, chicks received a secondary immunization with a commercial live Ark-IBV vaccine at 14 days of age. Immunological responses were determined two weeks after secondary vaccination. Antibody titers were highest in birds receiving either of the largest two DNA amounts. The proportions of T-lymphocytes expressing CD4<super>+</super> or CD8<super>+</super> in the spleen was examined by flow cytometry. The proportion of CD4<super>+</super>/CD8<super>+</super> cells was approximately 1:2 in birds receiving 300 μg of DNA alone, whereas a ratio of almost 1:1 was detected in birds immunized with 300 μg of DNA in a transfection reagent.
520 $a To examine protective immunity following <italic>in ovo</italic> immunization, chicken embryos received pDKArkS1-DPI at 18 days of age, followed by live virus vaccine or pDKArkS1-DPI at 2 weeks-of-age. Birds receiving only live virus vaccine or only <italic>in ovo</italic> DNA vaccination were ≤80% protected. Negative control group birds were ≤50% protected from clinical disease. These data indicate <italic>in ovo</italic> DNA vaccination can increase protective and local immunity against IBV infection.
590 $a School code: 0077.
650 4 $a Biology, Microbiology. $3 1017734
650 4 $a Biology, Veterinary Science. $3 1021733
690 $a 0410
690 $a 0778
710 2 0 $a University of Georgia. $3 515076
773 0 $t Dissertation Abstracts International $g 60-11B.
790 1 0 $a Jackwood, Mark W., $e advisor
790 $a 0077
791 $a Ph.D.
792 $a 1998
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=9949454